Das SC - Search Results

1

In vitro Dissolution Testing of Rifampicin Powder Formulations For Prediction of Plasma Concentration-Time Profiles After Inhaled Delivery.

Khadka P, Tucker IG, Das SC. Khadka P, et al. Among authors: das sc. Pharm Res. 2023 May;40(5):1153-1163. doi: 10.1007/s11095-022-03439-z. Epub 2022 Nov 29. Pharm Res. 2023. PMID: 36447019

2

Powder strength distributions for understanding de-agglomeration of lactose powders.

Das SC, Behara SR, Bulitta JB, Morton DA, Larson I, Stewart PJ. Das SC, et al. Pharm Res. 2012 Oct;29(10):2926-35. doi: 10.1007/s11095-012-0799-0. Epub 2012 Jun 14. Pharm Res. 2012. PMID: 22695732

3

Inhaled dry powder formulations for treating tuberculosis.

Das S, Tucker I, Stewart P. Das S, et al. Curr Drug Deliv. 2015;12(1):26-39. doi: 10.2174/1567201811666140716123050. Curr Drug Deliv. 2015. PMID: 25030114 Review.

4

Surface Energy Determined by Inverse Gas Chromatography as a Tool to Investigate Particulate Interactions in Dry Powder Inhalers.

Das SC, Tucker IG, Stewart PJ. Das SC, et al. Curr Pharm Des. 2015;21(27):3932-44. doi: 10.2174/1381612821666150820110046. Curr Pharm Des. 2015. PMID: 26290201 Review.

5

Phospholipid-based pyrazinamide spray-dried inhalable powders for treating tuberculosis.

Eedara BB, Tucker IG, Das SC. Eedara BB, et al. Among authors: das sc. Int J Pharm. 2016 Jun 15;506(1-2):174-83. doi: 10.1016/j.ijpharm.2016.04.038. Epub 2016 Apr 28. Int J Pharm. 2016. PMID: 27091294

6

Dry powder formulation of kanamycin with enhanced aerosolization efficiency for drug-resistant tuberculosis.

Momin MAM, Sinha S, Tucker IG, Doyle C, Das SC. Momin MAM, et al. Among authors: das sc. Int J Pharm. 2017 Aug 7;528(1-2):107-117. doi: 10.1016/j.ijpharm.2017.06.004. Epub 2017 Jun 3. Int J Pharm. 2017. PMID: 28583333

7

Co-spray drying of hygroscopic kanamycin with the hydrophobic drug rifampicin to improve the aerosolization of kanamycin powder for treating respiratory infections.

Momin MAM, Tucker IG, Doyle CS, Denman JA, Sinha S, Das SC. Momin MAM, et al. Among authors: das sc. Int J Pharm. 2018 Apr 25;541(1-2):26-36. doi: 10.1016/j.ijpharm.2018.02.026. Epub 2018 Feb 17. Int J Pharm. 2018. PMID: 29458207

8

Manipulation of spray-drying conditions to develop dry powder particles with surfaces enriched in hydrophobic material to achieve high aerosolization of a hygroscopic drug.

Momin MAM, Tucker IG, Doyle CS, Denman JA, Das SC. Momin MAM, et al. Among authors: das sc. Int J Pharm. 2018 May 30;543(1-2):318-327. doi: 10.1016/j.ijpharm.2018.04.003. Epub 2018 Apr 4. Int J Pharm. 2018. PMID: 29626509

9

Considerations in preparing for clinical studies of inhaled rifampicin to enhance tuberculosis treatment.

Khadka P, Dummer J, Hill PC, Das SC. Khadka P, et al. Among authors: das sc. Int J Pharm. 2018 Sep 5;548(1):244-254. doi: 10.1016/j.ijpharm.2018.07.011. Epub 2018 Jul 3. Int J Pharm. 2018. PMID: 29983396 Review.

10

High dose dry powder inhalers to overcome the challenges of tuberculosis treatment.

Momin MAM, Tucker IG, Das SC. Momin MAM, et al. Among authors: das sc. Int J Pharm. 2018 Oct 25;550(1-2):398-417. doi: 10.1016/j.ijpharm.2018.08.061. Epub 2018 Sep 1. Int J Pharm. 2018. PMID: 30179703 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

254 results

Search Page

Filters